{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "24977664",
  "DateCompleted": {
    "Year": "2015",
    "Month": "12",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "03",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.2340/00015555-1918"
    ],
    "Journal": {
      "ISSN": "1651-2057",
      "JournalIssue": {
        "Volume": "95",
        "Issue": "3",
        "PubDate": {
          "Year": "2015",
          "Month": "Mar"
        }
      },
      "Title": "Acta dermato-venereologica",
      "ISOAbbreviation": "Acta Derm Venereol"
    },
    "ArticleTitle": "Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one-year study.",
    "Pagination": {
      "StartPage": "278",
      "EndPage": "282",
      "MedlinePgn": "278-82"
    },
    "Abstract": {
      "AbstractText": [
        "Cold contact urticaria is the second most common subtype of physical urticaria. Cold stimulation standardized tests are mandatory to confirm the diagnosis. The aim of this study is to define the utility of determining thresholds (critical time and temperature) in assessment of the clinical course of typical acquired cold contact urticaria. Nineteen adult patients (10 women and 9 men; mean age 45 years) were included in the study and the diagnosis was confirmed with the ice-cube test and TempTest 3.0. Patients were treated continuously for 1 year with 20 mg/day rupatadine (anti-H1). Thresholds measurements were made before and after treatment. Improvements in temperature and critical time thresholds were found in the study sample, demonstrating the efficacy of continuous treatment with rupatadine. In most cases association with a clinical improvement was found. We propose an algorithm for the management of acquired cold contact urticaria based on these results."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Institut Municipal d'Investigaci\u00f3 M\u00e8dica, Barcelona, Spain."
          }
        ],
        "LastName": "Martinez-Escala",
        "ForeName": "M Estela",
        "Initials": "ME"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Curto-Barredo",
        "ForeName": "Laia",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Carnero",
        "ForeName": "Llu\u00efsa",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pujol",
        "ForeName": "Ramon M",
        "Initials": "RM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gim\u00e9nez-Arnau",
        "ForeName": "Ana M",
        "Initials": "AM"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Observational Study"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Sweden",
    "MedlineTA": "Acta Derm Venereol",
    "NlmUniqueID": "0370310",
    "ISSNLinking": "0001-5555"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Histamine H1 Antagonists, Non-Sedating"
    },
    {
      "RegistryNumber": "2AE8M83G3E",
      "NameOfSubstance": "rupatadine"
    },
    {
      "RegistryNumber": "2YHB6175DO",
      "NameOfSubstance": "Cyproheptadine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Algorithms"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Cold Temperature"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Critical Pathways"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "therapeutic use"
      ],
      "DescriptorName": "Cyproheptadine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Histamine H1 Antagonists, Non-Sedating"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Predictive Value of Tests"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sensory Thresholds"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Thermosensing"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "etiology",
        "psychology"
      ],
      "DescriptorName": "Urticaria"
    }
  ]
}